Science News

Tsinghua Develops Long-Lived CAR-T Cells for Single-Dose Obesity & Diabetes Therapy Semaglutide Biotech CAR-T Diabetes Tirzepatide Tsinghua University develops long-lived CAR-T cells that enable single-dose, long-term treatment of obesity and diabetes, offering a potential one-time therapy for chronic diseases.
CD19 Targeted Drugs: A "Lifeline" for Lymphoma Patients? Biotech Explore how CD19-targeted CAR-T and CAR-NK cell therapies are transforming treatment for relapsed/refractory B-cell lymphoma. Learn about their mechanisms, clinical outcomes, safety profiles, and future potential in cancer care.
Stem Cell Therapy: 5 Major Challenges Biotech Explore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
Breakthrough Vitiligo Treatment: Shanghai Jiao Tong University Identifies New Target and Achieves Promising Clinical Trial Results Vitiligo Ruxolitinib Researchers from Shanghai Jiao Tong University have discovered a new vitiligo treatment target involving the CGRP-cDC1-CD8+ T cell axis. Clinical trials with Rimegepant ointment show promising results for skin repigmentation.
New Study: Can Taurine in Energy Drinks Accelerate Leukemia Progression? Taurine A new study in Nature reveals taurine in energy drinks may aid leukemia cell growth. While safe for most, high-risk individuals should be cautious. Learn who should avoid excess taurine and why sugar might be a bigger concern.
Radioligand Therapy in Oncology: Latest Advances in Targeted Radiopharmaceuticals from Nature Report Biotech Radiopharmaceuticals Explore the latest Nature report on radioligand therapy (RLT) in oncology. Learn about innovations in isotopes, targeting ligands, and clinical pipelines driving the next wave of targeted radiopharmaceuticals.
Why Can Our Liver Regenerate? Key Gene Mechanisms in Liver Regeneration | Latest Cell Genomics Research Biotech Discover how the liver regenerates through key gene regulatory mechanisms revealed by latest research in Cell Genomics. Learn about enhancers and transcription factors driving liver regeneration.
NEJM Study: Exercise Boosts Colon Cancer Survival Comparable to Drugs Cancer A groundbreaking NEJM phase 3 trial confirms structured exercise significantly improves survival and reduces recurrence in colon cancer patients—comparable to some anti-cancer drugs.
Age-associated NAD Decline Drives CAR-T Cell Therapy Failure CAR-T Nicotinamide adenine dinucleotide Aging-related decline in NAD levels impairs CAR-T cell therapy effectiveness. Restoring NAD metabolism enhances mitochondrial function and offers a promising strategy to improve CAR-T treatment outcomes in elderly patients.
Chinese Original Weight Loss Drug Featured in NEJM Semaglutide Innoventbio Mazdutide "Mazdutide, a Chinese-developed dual GLP-1/GCG receptor agonist, shows strong weight loss efficacy and safety in a NEJM-published trial, outperforming semaglutide with fewer side effects.